Fujitani S, Ikenoue T, Akiyoshi M, Maki T, Yada T
Life Science Laboratories, Central Research Laboratories, Yokohama, Japan.
Metabolism. 1996 Feb;45(2):184-9. doi: 10.1016/s0026-0495(96)90051-7.
N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166) is a nonsulfonylurea hypoglycemic agent that decreases blood glucose levels in nondiabetic and diabetic animals. In the present study, we attempted to determine the effect of A-4166 on hormone secretion from the in vitro-perfused rat pancreas and to examine the underlying secretory mechanisms. In the presence of basal glucose (3 mmol/L), A-4166 markedly stimulated insulin and somatostatin release in a concentration-dependent manner over 0.03 to 3 mmol/L. A sulfonylurea, tolbutamide, also stimulated insulin and somatostatin release. A-4166 and tolbutamide elevated the level of glucagon release; however, the change lacked a clear concentration-dependent property. A-4166 at 0.3 mmol/L and tolbutamide at 3 mmol/L exhibited maximal stimulation of insulin release to a similar extent, indicating that A-4166 is one log-order more potent than and as effective as tolbutamide. By contrast, A-4166 stimulated somatostatin release to a threefold greater extent than tolbutamide. A-4166 evoked an increase in the cytosolic free-Ca2+ concentration ([Ca2+]i) in rat pancreatic beta cells. [Ca2+]i and insulin secretory responses to A-4166 were inhibited by nitrendipine (NTD), a blocker of the L-type Ca2+ channel, and by diazoxide (DAZ), an opener of the adenosine triphosphate (ATP)-sensitive K+ channel. Furthermore, A-4166-stimulated somatostatin release was also inhibited by NTD and by DAZ. The results indicate that A-4166 and tolbutamide stimulate the release of insulin and somatostatin, and that A-4166 is much more effective than tolbutamide in releasing somatostatin, a hormone that attenuates hyperglycemia under certain circumstances. It is concluded that A-4166-induced insulin release is mediated by an increase in [Ca2+]i in beta cells. An inhibition of ATP-sensitive K+ channels and a consequent activation of L-type Ca2+ channels appear to play a key role not only in insulin secretion from beta cells, but also in somatostatin secretion from delta cells in response to A-4166.
N-[(反式-4-异丙基环己基)-羰基]-D-苯丙氨酸(A-4166)是一种非磺酰脲类降糖药,可降低非糖尿病和糖尿病动物的血糖水平。在本研究中,我们试图确定A-4166对体外灌注大鼠胰腺激素分泌的影响,并研究其潜在的分泌机制。在基础葡萄糖(3 mmol/L)存在的情况下,A-4166在0.03至3 mmol/L浓度范围内以浓度依赖性方式显著刺激胰岛素和生长抑素释放。磺酰脲类药物甲苯磺丁脲也刺激胰岛素和生长抑素释放。A-4166和甲苯磺丁脲提高了胰高血糖素释放水平;然而,这种变化缺乏明显的浓度依赖性。0.3 mmol/L的A-4166和3 mmol/L的甲苯磺丁脲对胰岛素释放的刺激程度相似,表明A-4166的效力比甲苯磺丁脲高一个数量级且效果相同。相比之下,A-4166刺激生长抑素释放的程度比甲苯磺丁脲高两倍。A-4166引起大鼠胰腺β细胞胞质游离Ca2+浓度([Ca2+]i)升高。L型Ca2+通道阻滞剂尼群地平(NTD)和三磷酸腺苷(ATP)敏感性钾通道开放剂二氮嗪(DAZ)抑制了[Ca2+]i和对A-4166的胰岛素分泌反应。此外,NTD和DAZ也抑制了A-4166刺激的生长抑素释放。结果表明,A-4166和甲苯磺丁脲刺激胰岛素和生长抑素释放,并且A-4166在释放生长抑素方面比甲苯磺丁脲有效得多,生长抑素在某些情况下可减轻高血糖。结论是,A-4166诱导的胰岛素释放是由β细胞中[Ca2+]i升高介导的。ATP敏感性钾通道的抑制以及随之而来的L型Ca2+通道的激活似乎不仅在β细胞的胰岛素分泌中起关键作用,而且在δ细胞对A-4166的生长抑素分泌中也起关键作用。